GSM7980103[Accession] - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Search results

Items: 3

Select item 2002505091.

Protein expression from paired biopsies from a patient with METex14 skiping non-small cell lung cancer before and after treatment with neoadjuvant tepotinib (42 days)

(Submitter supplied) Background: MET inhibitors have demonstrated efficacy in treating patients with non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Advancements in spatial profiling technologies have unveiled the complex dynamics of the tumor microenvironment, a crucial factor in cancer progression and therapeutic response. Using spatial profiling, this study investigates the effects of the MET inhibitor tepotinib on the TME in a case of locally advanced NSCLC with a METex14 skipping alteration. more...

Organism:: Homo sapiens

Type:: Other

Platform:: GPL34024
94 Samples

Download data: XLSX

Series

Accession:: GSE250509

ID:: 200250509

Analyze with GEO2R

Select item 1000340242.

GeoMx Digital Spatial Profiler (DSP): Immune Profiling, Typing, Activation, IO Drug Targets, PI3K/AKT protein panels

(Submitter supplied) GeoMx Digital Spatial Profiler (DSP): Immune Cell Profiling, Cell Typing, Activation Status, IO Drug Targets, PI3K/AKT Signaling protein panels Protocol: See manufacturer's website